Publications & News

Improving Diversity & Inclusion: ASHG’s New Policy Statement

March 2020 In May 2019, ASHG leadership released the Society’s 2019-23 Strategic Plan, a document driving the next few years of Society priorities that outlines key avenues to advance the field and benefit members. To help achieve the Society’s vision that people everywhere realize the benefits of human genetics and genomics research, we understood that diversity and inclusion would need to be a priority.   There is a growing recognition that when the genetic diversity of humans... Read More

Michael Bamshad, MD

Michael Bamshad, Human Genetics and Genomics Advances Editor-in-Chief, on ASHG’s New Open Access Journal 

March 2020 Human Genetics and Genomics Advances (HGG Advances), the newest member of the ASHG family, is a high-quality, society-led open access (OA) publishing option for the research community. Michael Bamshad, MD, will lead the journal as Editor-in Chief.  The way that human genetics research is done is rapidly changing, characterized by more collaborative, networked,... Read More

Get to Know Kate Garber, Educator and Science Communicator

Posted By: Evelyn Mantegani, Public Education & Engagement Specialist, ASHG   Kate Garber, PhD, is a member of the GENE Network and co-chair of the ASHG Public Education & Awareness Committee. She is on the faculty at Emory University in Atlanta, where she runs the genetics curriculum for medical and physician assistant students and directs... Read More

Efforts to Indigenize Genomics with Support of the HGSI

Posted By: Krystal Tsosie, MPH, MA, 2019-21 Human Genetics Scholar As an ASHG Human Genetics Scholars Initiative awardee, I want to thank the Society for enabling my international research endeavors to connect globally with Indigenous scholars. I was invited to present at the SING Indigenous Genomics conference at the University of Waikato in New Zealand... Read More

Ethical Implications of the Novartis Lottery

Nascent Transcript Author: Anna Miller A recent decision by the pharmaceutical company Novartis to provide 100 free gene therapy treatments for spinal muscular atrophy (SMA), a debilitating yet rare genetic condition, to patients selected through a lottery program has sparked debate about the ethical implications. SMA is a rare autosomal recessive genetic disorder caused by... Read More

ASHG uses cookies to provide you with a secure and custom web experience. Privacy Policy